Betahistine
- Generic Name
- Betahistine
- Brand Names
- Serc
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N2
- CAS Number
- 5638-76-6
- Unique Ingredient Identifier
- X32KK4201D
- Background
Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing loss. It has a significant impact on both the physical and social functioning of affected individuals.
...
- Indication
Betahistine is indicated for the reduction of recurrent vertigo episodes associated with Ménière's disease in patients 18 years old and above.
- Associated Conditions
- Menière's Disease
- Associated Therapies
- -
Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06001593
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 15
- Registration Number
- NCT05938517
- Locations
- 🇩🇪
Department of Neurology, Ludwig Maximilian University, Munich, Bavaria, Germany
Interventions for Residual Dizziness After Successful Repositioning Maneuvers in Patients With BPPV
- Conditions
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Eye & ENT Hospital of Fudan University
- Target Recruit Count
- 183
- Registration Number
- NCT03624283
- Locations
- 🇨🇳
Otorhinolaryngology Department of Affiliated Eye and ENT Hospital, Fudan University, Shanghai, China, Shanghai, Shanghai, China
The CBF Study Evaluating the Effect of Betahistine on the Cerebral Blood Flow
- Conditions
- Interventions
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Abbott Products
- Target Recruit Count
- 27
- Registration Number
- NCT01468285
- Locations
- 🇸🇬
Site Reference ID/Investigator# 63545, Singapore, Singapore
🇸🇬Site Reference ID/Investigator# 63544, Singapore, Singapore
Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2009-05-05
- Lead Sponsor
- OBEcure Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT00852956
- Locations
- 🇷🇴
IFE Human Pharmacology, Timisoara, Romania
Efficacy Study of Betahistine on Body Weight in Obese Female Subjects
- First Posted Date
- 2008-09-08
- Last Posted Date
- 2009-05-07
- Lead Sponsor
- OBEcure Ltd.
- Target Recruit Count
- 187
- Registration Number
- NCT00748436
- Locations
- 🇳🇱
GP: Dr. Rol, Bennebroek, Netherlands
🇳🇱AMWO, Rotterdam, Netherlands
🇧🇪GP: Dr. Van Mulders, Aalst, Belgium
Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight Gain
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Nathan Kline Institute for Psychiatric Research
- Target Recruit Count
- 48
- Registration Number
- NCT00709202
- Locations
- 🇺🇸
Nathan Kline Insitute for Psychiatric Research, Orangeburg, New York, United States
Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features
- Conditions
- Interventions
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 1
- Registration Number
- NCT00585585
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
A Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effect of Betahistine on Plasma Lipids in Patients Treated With Simvastatin
- Conditions
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2007-09-26
- Lead Sponsor
- OBEcure Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT00466869
- Locations
- 🇮🇱
Internal Medicine Department A-Wolfson Medical Center, Holon, Israel
🇮🇱Internal Medicine Department A-Meir Medical Center, Kfar Saba, Israel
Study to Examine the Effect of Betahistine on Body Weight Gain Due to Olanzapine Treatment
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- OBEcure Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT00428168
- Locations
- 🇨🇦
Dr. Ivan Kowalchuk, Winnipeg, Manitoba, Canada
🇮🇱Abarbanel Hospital, Bat Yam, Israel
🇨🇦Queen's University, Kingston, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.